{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T07:43:16Z","timestamp":1778226196264,"version":"3.51.4"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:00:00Z","timestamp":1677715200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T00:00:00Z","timestamp":1677715200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA251438"],"award-info":[{"award-number":["R01CA251438"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Med Oncol"],"DOI":"10.1007\/s12032-023-01975-1","type":"journal-article","created":{"date-parts":[[2023,3,2]],"date-time":"2023-03-02T08:02:46Z","timestamp":1677744166000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Stem cell-assisted enzyme\/prodrug therapy makes drug-resistant ovarian cancer cells vulnerable to natural killer cells through upregulation of NKG2D ligands"],"prefix":"10.1007","volume":"40","author":[{"given":"Geng","family":"Li","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahryar Khoshtinat","family":"Nikkhoi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4611-7469","authenticated-orcid":false,"given":"Arash","family":"Hatefi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,2]]},"reference":[{"key":"1975_CR1","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.ygyno.2013.12.002","volume":"132","author":"V da Costa Miranda","year":"2014","unstructured":"da Costa Miranda V, de Souza Fede AB, Dos Anjos CH, da Silva JR, Sanchez FB, da Silva Bessa LR, de Paula Carvalho J, Filho EA, de Freitas D, Del Pilar Estevez M, Diz. Neoadjuvant chemotherapy with six cycles of carboplatin and paclitaxel in advanced ovarian cancer patients unsuitable for primary surgery: safety and effectiveness. Gynecol Oncol. 2014;132:287\u201391.","journal-title":"Gynecol Oncol"},{"key":"1975_CR2","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ygyno.2012.09.013","volume":"128","author":"I Vergote","year":"2013","unstructured":"Vergote I, du Bois A, Amant F, Heitz F, Leunen K, Harter P. Neoadjuvant chemotherapy in advanced ovarian cancer: on what do we agree and disagree? Gynecol Oncol. 2013;128:6\u201311.","journal-title":"Gynecol Oncol"},{"key":"1975_CR3","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ygyno.2013.12.001","volume":"132","author":"MM Shah","year":"2014","unstructured":"Shah MM, Landen CN. Ovarian cancer stem cells: are they real and why are they important? Gynecol Oncol. 2014;132:483\u20139.","journal-title":"Gynecol Oncol"},{"issue":"1","key":"1975_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2012.02.002","volume":"322","author":"D Burgos-Ojeda","year":"2012","unstructured":"Burgos-Ojeda D, Rueda BR, Buckanovich RJ. Ovarian cancer stem cell markers: prognostic and therapeutic implications. Cancer Lett. 2012;322(1):1\u20137.","journal-title":"Cancer Lett"},{"key":"1975_CR5","doi-asserted-by":"publisher","DOI":"10.1016\/j.ygyno.2013.12.001","author":"MM Shah","year":"2013","unstructured":"Shah MM, Landen CN. Ovarian cancer stem cells: Are they real and why are they important? Gynecol Oncol. 2013. https:\/\/doi.org\/10.1016\/j.ygyno.2013.12.001.","journal-title":"Gynecol Oncol"},{"key":"1975_CR6","doi-asserted-by":"publisher","first-page":"537","DOI":"10.7150\/jca.15989","volume":"8","author":"AK Kozlowska","year":"2017","unstructured":"Kozlowska AK, Topchyan P, Kaur K, Tseng HC, Teruel A, Hiraga T, Jewett A. Differentiation by NK cells is a prerequisite for effective targeting of cancer stem cells\/poorly differentiated tumors by chemopreventive and chemotherapeutic drugs. J Cancer. 2017;8:537\u201354.","journal-title":"J Cancer"},{"key":"1975_CR7","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40425-016-0124-2","volume":"4","author":"SK Grossenbacher","year":"2016","unstructured":"Grossenbacher SK, Canter RJ, Murphy WJ. Natural killer cell immunotherapy to target stem-like tumor cells. J Immunother Cancer. 2016;4:19.","journal-title":"J Immunother Cancer"},{"key":"1975_CR8","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00262-008-0585-3","volume":"58","author":"K Li","year":"2009","unstructured":"Li K, Mandai M, Hamanishi J, Matsumura N, Suzuki A, Yagi H, Yamaguchi K, Baba T, Fujii S, Konishi I. Clinical significance of the NKG2D ligands, MICA\/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol Immunother. 2009;58:641\u201352.","journal-title":"Cancer Immunol Immunother"},{"key":"1975_CR9","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1038\/nri1199","volume":"3","author":"DH Raulet","year":"2003","unstructured":"Raulet DH. Roles of the NKG2D immunoreceptor and its ligands. Nat Rev Immunol. 2003;3:781\u201390.","journal-title":"Nat Rev Immunol"},{"key":"1975_CR10","doi-asserted-by":"publisher","first-page":"e1339854","DOI":"10.1080\/2162402X.2017.1339854","volume":"6","author":"M Vyas","year":"2017","unstructured":"Vyas M, Reinartz S, Hoffmann N, Reiners KS, Lieber S, Jansen JM, Wagner U, Muller R, von Strandmann EP. Soluble NKG2D ligands in the ovarian cancer microenvironment are associated with an adverse clinical outcome and decreased memory effector T cells independent of NKG2D downregulation. Oncoimmunology. 2017;6:e1339854.","journal-title":"Oncoimmunology"},{"key":"1975_CR11","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/cmi.2014.30","volume":"11","author":"J Xie","year":"2014","unstructured":"Xie J, Liu M, Li Y, Nie Y, Mi Q, Zhao S. Ovarian tumor-associated microRNA-20a decreases natural killer cell cytotoxicity by downregulating MICA\/B expression. Cell Mol Immunol. 2014;11:495\u2013502.","journal-title":"Cell Mol Immunol"},{"key":"1975_CR12","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.ygyno.2020.03.020","volume":"157","author":"JS Hoogstad-van Evert","year":"2020","unstructured":"Hoogstad-van Evert JS, Bekkers R, Ottevanger N, Jansen JH, Massuger L, Dolstra H. Harnessing natural killer cells for the treatment of ovarian cancer. Gynecol Oncol. 2020;157:810\u20136.","journal-title":"Gynecol Oncol"},{"key":"1975_CR13","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.1038\/nature03884","volume":"436","author":"S Gasser","year":"2005","unstructured":"Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature. 2005;436:1186\u201390.","journal-title":"Nature"},{"key":"1975_CR14","doi-asserted-by":"publisher","first-page":"49509","DOI":"10.18632\/oncotarget.10375","volume":"7","author":"M Ke","year":"2016","unstructured":"Ke M, Wang H, Zhou Y, Li J, Liu Y, Zhang M, Dou J, Xi T, Shen B, Zhou C. SEP enhanced the antitumor activity of 5-fluorouracil by up-regulating NKG2D\/MICA and reversed immune suppression via inhibiting ROS and caspase-3 in mice. Oncotarget. 2016;7:49509\u201326.","journal-title":"Oncotarget"},{"key":"1975_CR15","first-page":"945","volume":"19","author":"K Takeda","year":"2008","unstructured":"Takeda K, Suyama H, Igishi T, Shigeoka Y, Matsumoto S, Yamasaki A, Hashimoto K, Sumikawa T, Morita M, Ueda Y, Shimizu E. Sequential treatment with SN-38 followed by 5-fluorouracil shows synergistic cytotoxic activity in small cell lung cancer cells. Oncol Rep. 2008;19:945\u201351.","journal-title":"Oncol Rep"},{"key":"1975_CR16","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3892\/or.2010.835","volume":"24","author":"M Fukushima","year":"2010","unstructured":"Fukushima M, Sakamoto K, Ohshimo H, Nakagawa F, Taguchi T. Irinotecan overcomes the resistance to 5-fluorouracil in human colon cancer xenografts by down-regulation of intratumoral thymidylate synthase. Oncol Rep. 2010;24:835\u201342.","journal-title":"Oncol Rep"},{"key":"1975_CR17","first-page":"19","volume":"12","author":"J Lokich","year":"1998","unstructured":"Lokich J. Infusional 5-FU: historical evolution, rationale, and clinical experience. Oncology (Williston Park). 1998;12:19\u201322.","journal-title":"Oncology (Williston Park)"},{"key":"1975_CR18","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1097\/GCO.0000000000000432","volume":"30","author":"MP Campos","year":"2018","unstructured":"Campos MP, Konecny GE. The target invites a foe: antibody-drug conjugates in gynecologic oncology. Curr Opin Obstet Gynecol. 2018;30:44\u201350.","journal-title":"Curr Opin Obstet Gynecol"},{"key":"1975_CR19","doi-asserted-by":"publisher","first-page":"273","DOI":"10.1016\/j.jconrel.2019.09.006","volume":"311\u2013312","author":"OM Malekshah","year":"2019","unstructured":"Malekshah OM, Sarkar S, Nomani A, Patel N, Javidian P, Goedken M, Polunas M, Louro P, Hatefi A. Bioengineered adipose-derived stem cells for targeted enzyme-prodrug therapy of ovarian cancer intraperitoneal metastasis. J Control Release. 2019;311\u2013312:273\u201387.","journal-title":"J Control Release"},{"key":"1975_CR20","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1016\/j.jconrel.2015.01.003","volume":"200","author":"FS Nouri","year":"2015","unstructured":"Nouri FS, Wang X, Hatefi A. Genetically engineered theranostic mesenchymal stem cells for the evaluation of the anticancer efficacy of enzyme\/prodrug systems. J Control Release. 2015;200:179\u201387.","journal-title":"J Control Release"},{"key":"1975_CR21","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.addr.2015.05.009","volume":"99","author":"Z Karjoo","year":"2016","unstructured":"Karjoo Z, Chen X, Hatefi A. Progress and problems with the use of suicide genes for targeted cancer therapy. Adv Drug Deliv Rev. 2016;99:113\u201328.","journal-title":"Adv Drug Deliv Rev"},{"key":"1975_CR22","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s40495-016-0073-y","volume":"2","author":"OM Malekshah","year":"2016","unstructured":"Malekshah OM, Chen X, Nomani A, Sarkar S, Hatefi A. Enzyme\/prodrug systems for cancer gene therapy. Current pharmacol reports. 2016;2:299\u2013308.","journal-title":"Current pharmacol reports"},{"key":"1975_CR23","doi-asserted-by":"publisher","first-page":"3630","DOI":"10.1002\/cam4.1631","volume":"7","author":"S Sarkar","year":"2018","unstructured":"Sarkar S, Malekshah OM, Nomani A, Patel N, Hatefi A. A novel chemotherapeutic protocol for peritoneal metastasis and inhibition of relapse in drug resistant ovarian cancer. Cancer Med. 2018;7:3630\u201341.","journal-title":"Cancer Med"},{"key":"1975_CR24","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0022-1759(98)00028-3","volume":"213","author":"MM Nociari","year":"1998","unstructured":"Nociari MM, Shalev A, Benias P, Russo C. A novel one-step, highly sensitive fluorometric assay to evaluate cell-mediated cytotoxicity. J Immunol Methods. 1998;213:157\u201367.","journal-title":"J Immunol Methods"},{"key":"1975_CR25","doi-asserted-by":"publisher","first-page":"e107739","DOI":"10.15252\/embj.2021107739","volume":"41","author":"J Fan","year":"2022","unstructured":"Fan J, Shi J, Zhang Y, Liu J, An C, Zhu H, Wu P, Hu W, Qin R, Yao D, Shou X, Xu Y, Tong Z, Wen X, Xu J, Zhang J, Fang W, Lou J, Yin W, Chen W. NKG2D discriminates diverse ligands through selectively mechano-regulated ligand conformational changes. EMBO J. 2022;41:e107739.","journal-title":"EMBO J"},{"key":"1975_CR26","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.ebiom.2019.01.031","volume":"40","author":"N Mensali","year":"2019","unstructured":"Mensali N, Dillard P, Hebeisen M, Lorenz S, Theodossiou T, Myhre MR, Fane A, Gaudernack G, Kvalheim G, Myklebust JH, Inderberg EM, Walchli S. NK cells specifically TCR-dressed to kill cancer cells. EBioMedicine. 2019;40:106\u201317.","journal-title":"EBioMedicine"},{"key":"1975_CR27","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1089\/152581601750288975","volume":"10","author":"G Maki","year":"2001","unstructured":"Maki G, Klingemann HG, Martinson JA, Tam YK. Factors regulating the cytotoxic activity of the human natural killer cell line, NK-92. J Hematother Stem Cell Res. 2001;10:369\u201383.","journal-title":"J Hematother Stem Cell Res"},{"key":"1975_CR28","doi-asserted-by":"publisher","DOI":"10.1242\/dmm.034199","author":"Y Klymenko","year":"2018","unstructured":"Klymenko Y, Wates RB, Weiss-Bilka H, Lombard R, Liu Y, Campbell L, Kim O, Wagner D, Ravosa MJ, Stack MS. Modeling the effect of ascites-induced compression on ovarian cancer multicellular aggregates. Dis Model Mech. 2018. https:\/\/doi.org\/10.1242\/dmm.034199.","journal-title":"Dis Model Mech"},{"key":"1975_CR29","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1016\/j.canlet.2016.11.034","volume":"388","author":"K Auer","year":"2017","unstructured":"Auer K, Bachmayr-Heyda A, Aust S, Grunt TW, Pils D. Comparative transcriptome analysis links distinct peritoneal tumor spread types, miliary and non-miliary, with putative origin, tubes and ovaries, in high grade serous ovarian cancer. Cancer Lett. 2017;388:158\u201366.","journal-title":"Cancer Lett"},{"key":"1975_CR30","first-page":"2083","volume":"29","author":"S Torigoe","year":"2009","unstructured":"Torigoe S, Ogata Y, Matono K, Shirouzu K. Molecular mechanisms of sequence-dependent antitumor effects of SN-38 and 5-fluorouracil combination therapy against colon cancer cells. Anticancer Res. 2009;29:2083\u20139.","journal-title":"Anticancer Res"},{"key":"1975_CR31","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1016\/j.apsb.2018.05.005","volume":"8","author":"D Wang","year":"2018","unstructured":"Wang D, Zou L, Jin Q, Hou J, Ge G, Yang L. Human carboxylesterases: a comprehensive review. Acta Pharm Sin B. 2018;8:699\u2013712.","journal-title":"Acta Pharm Sin B"},{"key":"1975_CR32","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1016\/j.ygyno.2005.10.013","volume":"100","author":"K Matsumoto","year":"2006","unstructured":"Matsumoto K, Katsumata N, Yamanaka Y, Yonemori K, Kohno T, Shimizu C, Andoh M, Fujiwara Y. The safety and efficacy of the weekly dosing of irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer. Gynecol Oncol. 2006;100:412\u20136.","journal-title":"Gynecol Oncol"},{"key":"1975_CR33","doi-asserted-by":"publisher","first-page":"96384","DOI":"10.18632\/oncotarget.21466","volume":"8","author":"Y Zhao","year":"2017","unstructured":"Zhao Y, Chen N, Yu Y, Zhou L, Niu C, Liu Y, Tian H, Lv Z, Han F, Cui J. Prognostic value of MICA\/B in cancers: a systematic review and meta-analysis. Oncotarget. 2017;8:96384\u201395.","journal-title":"Oncotarget"},{"key":"1975_CR34","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.3389\/fimmu.2018.02040","volume":"9","author":"D Schmiedel","year":"2018","unstructured":"Schmiedel D, Mandelboim O. NKG2D Ligands-Critical Targets for Cancer Immune Escape and Therapy. Front Immunol. 2018;9:2040.","journal-title":"Front Immunol"},{"key":"1975_CR35","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/S1074-7613(01)00095-4","volume":"14","author":"D Cosman","year":"2001","unstructured":"Cosman D, Mullberg J, Sutherland CL, Chin W, Armitage R, Fanslow W, Kubin M, Chalupny NJ. ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor. Immunity. 2001;14:123\u201333.","journal-title":"Immunity"},{"key":"1975_CR36","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1182\/blood-2005-11-011320","volume":"108","author":"CL Sutherland","year":"2006","unstructured":"Sutherland CL, Rabinovich B, Chalupny NJ, Brawand P, Miller R, Cosman D. ULBPs, human ligands of the NKG2D receptor, stimulate tumor immunity with enhancement by IL-15. Blood. 2006;108:1313\u20139.","journal-title":"Blood"},{"key":"1975_CR37","first-page":"687","volume":"7","author":"G Moncayo","year":"2016","unstructured":"Moncayo G, Lin D, McCarthy MT, Watson AA, O\u2019Callaghan CA. MICA Expression Is Regulated by Cell Adhesion and Contact in a FAK\/Src-Dependent Manner. Front Immunol. 2016;7:687.","journal-title":"Front Immunol"},{"key":"1975_CR38","doi-asserted-by":"publisher","first-page":"2016159","DOI":"10.1080\/2162402X.2021.2016159","volume":"11","author":"J Wang","year":"2022","unstructured":"Wang J, Liu K, Xiao T, Liu P, Prinz RA, Xu X. Uric acid accumulation in DNA-damaged tumor cells induces NKG2D ligand expression and antitumor immunity by activating TGF-beta-activated kinase 1. Oncoimmunology. 2022;11:2016159.","journal-title":"Oncoimmunology"},{"key":"1975_CR39","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.2174\/1389450117666160502151707","volume":"17","author":"K Gokduman","year":"2016","unstructured":"Gokduman K. Strategies Targeting DNA Topoisomerase I in Cancer Chemotherapy: Camptothecins, Nanocarriers for Camptothecins, Organic Non-Camptothecin Compounds and Metal Complexes. Curr Drug Targets. 2016;17:1928\u201339.","journal-title":"Curr Drug Targets"},{"key":"1975_CR40","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1517\/17425255.4.9.1153","volume":"4","author":"JM Hatfield","year":"2008","unstructured":"Hatfield JM, Wierdl M, Wadkins RM, Potter PM. Modifications of human carboxylesterase for improved prodrug activation. Expert Opin Drug Metab Toxicol. 2008;4:1153\u201365.","journal-title":"Expert Opin Drug Metab Toxicol"}],"container-title":["Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-01975-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12032-023-01975-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12032-023-01975-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T06:08:58Z","timestamp":1713766138000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12032-023-01975-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,2]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["1975"],"URL":"https:\/\/doi.org\/10.1007\/s12032-023-01975-1","relation":{},"ISSN":["1559-131X"],"issn-type":[{"value":"1559-131X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,2]]},"assertion":[{"value":"21 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Authors declare that they have no financial interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable. No human subjects or animals were used in this study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}}],"article-number":"110"}}